2816 related articles for article (PubMed ID: 35003058)
1. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
4. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity.
Lu J; Sun PD
J Biol Chem; 2020 Dec; 295(52):18579-18588. PubMed ID: 33122196
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
[TBL] [Abstract][Full Text] [Related]
6. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains.
Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T
mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537
[TBL] [Abstract][Full Text] [Related]
8. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
9. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
[TBL] [Abstract][Full Text] [Related]
11. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110
[TBL] [Abstract][Full Text] [Related]
12. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2.
Kiseleva AA; Troisi EM; Hensley SE; Kohli RM; Epstein JA
J Biochem; 2021 Oct; 170(2):299-306. PubMed ID: 33774672
[TBL] [Abstract][Full Text] [Related]
14. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
[TBL] [Abstract][Full Text] [Related]
15. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection.
Fuentes-Prior P
J Biol Chem; 2021; 296():100135. PubMed ID: 33268377
[TBL] [Abstract][Full Text] [Related]
16. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor.
Capraz T; Kienzl NF; Laurent E; Perthold JW; Föderl-Höbenreich E; Grünwald-Gruber C; Maresch D; Monteil V; Niederhöfer J; Wirnsberger G; Mirazimi A; Zatloukal K; Mach L; Penninger JM; Oostenbrink C; Stadlmann J
Elife; 2021 Dec; 10():. PubMed ID: 34927585
[TBL] [Abstract][Full Text] [Related]
18. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
19. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
